PatientID: HIVDR-1758-23

Sebuttemba 27, 2023

Color Code

HR: High-Level Resistance

LR: Low-Level Resistance

IR: Intermediate Resistance

S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
PI	ATV	S	
	DRV	${f S}$	
	FPV	${f S}$	
	IDV	${f S}$	
	LPV	${f S}$	
	NFV	\mathbf{S}	
	SQV	\mathbf{S}	
	TPV	\mathbf{S}	
NRTI	ABC	${f S}$	
	AZT	${f S}$	
	D4T	${f S}$	
	DDI	${f S}$	
	FTC	${f S}$	
	LMV	${f S}$	
	TDF	${f S}$	
NNRTI	DOR	$_{ m HR}$	
	EFV	$_{ m HR}$	
	ETR	$_{ m HR}$	K101E;Y181C;G190S
	NVP	$_{ m HR}$	
	RPV	$_{ m HR}$	

Appendix

Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
PI	IDV	Indinavir
11	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
NRTI	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
	DOR	Doravirine
	EFV	Efavirenz
NNRTI	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
	BIC	Bictegravir
	CAB	Cabotegravir
INSTI	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

Comments

DRUG.CLASS	COMMENTS
PI	
NRTI	
	G190S is a non-polymorphic mutation that confers high-level resistance to NVP and EFV.
	It may also be associated low-levels reductions in DOR susceptibility. It does not appear to
	be selected by ETR or RPV or to reduce their in vitro susceptibility.
	K101E is a non-polymorphic accessory mutation that confers intermediate resistance to
	NVP and RPV and low-level reductions in susceptibility to EFV, ETR, and DOR when it
NNRTI	occurs with other NNRTI-resistance mutations.
	Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV.
	It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and
	low-level resistance to EFV. It does not significantly reduce DOR susceptibility.
INSTI	